The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam - Test2 - elhamkhani - TriplyDB

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

http://www.wikidata.org/entity/Q24561949

about

Levetiracetam monotherapy for epilepsy New and emerging treatments for symptomatic tardive dyskinesia Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.Brivaracetam: a rational drug discovery success story Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures Modifications of antiepileptic drugs for improved tolerability and efficacy Levetiracetam in the treatment of epilepsy Diverse mechanisms of antiepileptic drugs in the development pipeline Molecular targets for antiepileptic drug development SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review The iTRAPs: Guardians of Synaptic Vesicle Cargo Retrieval During Endocytosis Profile of brivaracetam and its potential in the treatment of epilepsy Regulators of synaptic transmission: roles in the pathogenesis and treatment of epilepsy Traumatic Brain Injury pathophysiology and treatments: early, intermediate, and late phases post-injury Febrile seizures Modulating Behavior in C. elegans Using Electroshock and Antiepileptic Drugs A systems level, functional genomics analysis of chronic epilepsy Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond Current Status of the New Antiepileptic Drugs in Chronic Pain Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base Synaptopathies: synaptic dysfunction in neurological disorders - A review from students to students Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.Brivaracetam (UCB 34714)Seletracetam (UCB 44212)Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model Levetiracetam reverses synaptic deficits produced by overexpression of SV2A The antiepileptic drug levetiracetam suppresses non-convulsive seizure activity and reduces ischemic brain damage in rats subjected to permanent middle cerebral artery occlusion Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission Mutation of orthologous prickle genes causes a similar epilepsy syndrome in flies and humans.[Brivaracetam for add-on treatment in focal epilepsy].Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transporters Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid.Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders

P2860

Q24201619-26337409-8AF4-40B7-8E81-D6B18F9A4489 Q24599912-275EC3F1-A989-4AC3-9C2B-0A4D2AE68CE6 Q24624879-D9DCDF3A-F760-471B-903E-30CD10C30151 Q24642768-9A20B3D3-5651-4C60-89B0-2BC87F2A2224 Q24650880-A7B866D0-33BD-4105-9C4B-6C2B83294C29 Q24651951-ACEC0C07-7521-4626-983C-5E2195685B15 Q24656333-36E550C9-5011-4350-BC69-3E65CABD9F86 Q24675330-E24E897C-6E81-4F9B-85A2-5D1CC85570D3 Q24683346-0D3F2259-8591-4932-883C-7B45EF78572B Q26269919-79F04164-705C-4968-A392-5F030A055F96 Q26743786-2C4046D6-821B-4CD6-BF20-0A11EC6C04AC Q26768190-01F6EE66-EF2D-4E40-BDB3-41FB4404BCE8 Q26776317-053F6B20-9DA9-4C58-AA9F-101123C2BDDA Q26859135-98AA9FE1-AF9C-4ABE-A7C0-51040343849F Q27001739-1AF151CD-A507-4C33-9D1F-CC428B05DF2B Q27027264-CB36FDFC-2A51-4065-9BF8-D6141075DB15 Q27321178-9510CA45-69DF-4E62-8FDF-023ADCEAD499 Q27335505-9E6F1673-84C4-4392-8247-23FA8CFD4432 Q28068507-243B0B39-5BA3-4A7D-B62B-0521C41F7415 Q28070254-BA21DE25-ECFD-4023-BD4A-F01921E40F28 Q28076065-C9FA2A33-23D4-456A-B8F9-EEF40A19ADB4 Q28077671-7A76F50B-4F21-4C1C-9786-26F09C11E132 Q28083611-01ADD3E2-CA54-4DA2-817F-A3B79EE89790 Q28272717-69324905-428A-40B8-9EC2-2C8033CFF3CF Q28281249-A37CD7E7-4E67-4BAF-B96D-6FA99EC6DBC3 Q28281403-73D49285-1958-4A9D-A1D8-270ACCA76E7A Q28281424-66507377-8B62-4FA7-BDE1-6C04188ECAD9 Q28477672-CD1C0FA7-39EC-4839-AF9C-26D32FFCB9B1 Q28478633-51432061-198A-4B6F-A975-89CC305EA7B8 Q28535091-146C6D7C-D320-4513-8AF3-83C8EB54C423 Q28543500-1E1813FA-C033-4DE0-AE61-6168DFC1C1DB Q28553612-71BC3791-650A-44EF-B116-FF2EDC603278 Q29144205-F1F25821-CA5C-4C98-BF6D-05CAD17B7E4F Q30374282-A6483CF4-531A-4844-9916-C36392F2CA9D Q30390285-27CBC0D1-65AC-4A78-8309-390C142B8BAF Q30435547-2103569C-90AA-430B-B5A7-D530BE63E06B Q30440948-888437A0-AC42-45DD-9410-6199822B87C3 Q30479940-F5A33809-96DC-4EE0-8B54-BFE6B686C0C7 Q30494084-CED6226E-3131-4EB5-B9A8-C01DC5C19656 Q30611398-4BD6212D-6A47-44AE-89E0-A25C9ED62446

P2860

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

http://www.wikidata.org/entity/Q24561949

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@ast

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@en

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@nl

type

label

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@ast

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@en

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@nl

prefLabel

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@ast

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@en

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@nl

P1433

Q24561949-3300FD6F-5232-4C90-AC57-3583DF41CE52

P1476

Q24561949-5B13831D-AEDF-43A8-AB34-10A996BF6398

P2093

Q24561949-4BE129BC-1A24-4F22-B9D4-592B4F1B7F7D

Q24561949-57152AE1-DB34-4B21-8142-D7CF77AD13E4

Q24561949-659253D8-B71A-4F3F-9893-8FC9AF1BA4E6

Q24561949-7161DA34-B6E1-485E-9687-1FC8311B6CF7

Q24561949-8B53EEAA-7F36-4CAA-AFF5-D80E785935B9

Q24561949-8CE3EE67-7623-4570-A628-15D5D0BEA8E4

Q24561949-B7A89F37-6670-4EE5-B03F-A7077117F9B3

P2860

Q24561949-08F31179-7711-4E64-8A4F-9605B2698229

Q24561949-0DEAFE1C-D360-4DF6-85B2-8A09935FFE4B

Q24561949-10B80971-2A2C-4357-95B9-203D3F3F637E

Q24561949-1D53BD10-E191-4A61-97D9-18A6C84D67B9

Q24561949-33F80BD9-A5F3-4B80-8138-B2697FB18182

Q24561949-42DCA52A-4876-4B89-8B18-1ADD44A79C85

Q24561949-472135B1-617E-4DC0-A078-3F28585121EE

Q24561949-574E9DEB-26EC-4189-92B5-BB6D66A9B98A

Q24561949-6CBFCE51-1239-4205-9F16-05814BE8A014

Q24561949-7845419B-F601-46D5-9514-64EA7970248D

P304

Q24561949-A71DC63D-C21E-463E-8E01-5F203DA41DD7

P31

Q24561949-EAB9D58A-D4E8-426D-999A-B590566901FF

P3181

Q24561949-292EC7B3-64B4-40AC-9BA0-C8C3EA3CF0BE

P356

Q24561949-BCD78025-6AA3-4CB1-A556-059EF28E3510

P407

Q24561949-FB524265-CB13-4A55-8DB2-50AC5475F92E

P433

Q24561949-FF5C4B40-58DF-4856-8993-68677843C3FF

P478

Q24561949-C065C03F-F37C-4FB3-BF0E-60C40E1E6253

P577

Q24561949-7B58B270-1BD2-4AAB-86E0-86EFF5EB262A

P5875

Q24561949-835C8721-600C-425F-BC13-407427BBAF7A

P698

Q24561949-6A47EA73-62CB-4A33-9AB8-0E35BC654F57

P932

Q24561949-E074CCF3-2550-48E5-8D40-CE5F794E01B6

P3181

P356

PNAS.0308208101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

The synaptic vesicle protein S ...... tiepileptic drug levetiracetam

@en

P2093

Alain Matagne

http://www.w3.org/2001/XMLSchema#string

Berkley A Lynch

http://www.w3.org/2001/XMLSchema#string

Bruno Fuks

http://www.w3.org/2001/XMLSchema#string

Karl Nocka

http://www.w3.org/2001/XMLSchema#string

Nathalie Lambeng

http://www.w3.org/2001/XMLSchema#string

Patricia Kensel-Hammes

http://www.w3.org/2001/XMLSchema#string

Sandra M Bajjalieh

http://www.w3.org/2001/XMLSchema#string

P2860

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation

Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs

A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain

SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release

SV2, a brain synaptic vesicle protein homologous to bacterial transporters

Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

Changes in nitric oxide synthesis and epileptic activity in the contralateral hippocampus of rats following intrahippocampal kainate injection.

Moonlighting proteins: old proteins learning new tricks.

P304

9861-9866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

312837

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0308208101

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8497203

http://www.w3.org/2001/XMLSchema#string

P698

15210974

http://www.w3.org/2001/XMLSchema#string

P932

470764

http://www.w3.org/2001/XMLSchema#string